Drugs Made In America Acquisition Corp. entered into a Definitive Interim Investment and Sponsor Transition Agreement with BV Advisory Partners, LLC on March 23, 2026, issuing a $100,000 interim convertible note as the first tranche of a contemplated $500,000 financing. The proceeds are intended for expenses related to a potential business combination, and the investor has introduced a specific target opportunity involving an enterprise technology platform.
Key takeaways
The Company issued a $100,000 interim convertible note to BV Advisory Partners, LLC on March 23, 2026.
The note is the first tranche of a contemplated $500,000 financing, with a second tranche of $200,000 to be made within 21 days.
The note matures in six months, does not bear interest, and is convertible at the investor's option at a 35% discount to the post-merger market price.
The Company agreed to use commercially reasonable efforts to provide the investor with not less than 40% of the economic benefit equivalent to sponsor-level economics.
The investor introduced a potential business combination opportunity involving an enterprise technology platform focused on AI, ML, quantum analytics, and cybersecurity.
The Company's sponsor entity, Drugs Made In America Acquisition LLC, is non-operational and subject to legal constraints, and the Company is pursuing a replacement sponsor.